AzTrials
AzTrials

Gastroesophageal Reflux DiseaseNCT07809620

Preoperative Predictors of Symptom Improvement After Laparoscopic Fundoplication

An observational study of Gastroesophageal Reflux Disease and Hiatal Hernia, run by Minia University at 1 site in Egypt.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Laparoscopic fundoplication is the standard operation for gastroesophageal reflux disease (GERD) that does not respond adequately to medication, and it relieves reflux symptoms in most patients who are carefully selected for it. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Laparoscopic Nissen fundoplication and Laparoscopic Toupet fundoplication
Type of treatment
Surgery or procedure
How many people
470 participants
Where
1 siteEgypt
Study dates
20 Sep 2026to 20 Dec 2028
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Consecutive adults with objectively documented gastroesophageal reflux disease who are scheduled for elective laparoscopic fundoplication at a tertiary referral center for foregut surgery. Patients are identified and enrolled at the time of preoperative assessment.

Who may be able to join

  • Adults aged 18 years or older.
  • Objectively documented gastroesophageal reflux disease, defined by at least one of the following: pathological acid exposure on off-PPI 24-hour pH or pH-impedance monitoring; Los Angeles grade C or D esophagitis; biopsy-proven Barrett's esophagus; or a positive symptom-reflux association.
  • Medically refractory or PPI-dependent disease, troublesome regurgitation, or a symptomatic hiatal hernia, with an elective decision for laparoscopic fundoplication.
  • Able to provide written informed consent and to complete the study questionnaires.

Who cannot join

  • Previous antireflux or other major foregut or esophagogastric surgery.
  • Achalasia or a major esophageal motility disorder on high-resolution manometry (Chicago Classification version 4.0): absent contractility, esophagogastric junction outflow obstruction, distal esophageal spasm, or hypercontractile esophagus.
  • Giant or complex paraesophageal hernia requiring non-standard reconstruction, or a concurrent bariatric or other major intra-abdominal procedure.
  • Esophageal or gastric malignancy.
  • Emergency surgery.
  • Pregnancy.
  • Inability to complete patient-reported outcome instruments or to attend follow-up.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Egypt1 site, 1 recruiting
  • Minia University Hospitals - Department of Surgery, Faculty of Medicine, Minia University

    Minya, Minya Governorate, 61519

    Saleh K Saleh, MD, 01201765401 ext. +2, salehkhairy@mu.edu.eg

    Recruiting

Other trials in Egypt

About this study

Official title: Preoperative Predictors of Clinically Significant Symptom Improvement Twelve Months After Laparoscopic Fundoplication for Gastroesophageal Reflux Disease: A Prospective Observational Cohort Study

Laparoscopic fundoplication is the standard operation for gastroesophageal reflux disease (GERD) that does not respond adequately to medication, and it relieves reflux symptoms in most patients who are carefully selected for it. Even so, published studies consistently report that between 10% and 30% of patients continue to have symptoms afterwards, develop troublesome side effects such as difficulty swallowing or bloating, or are dissatisfied with the result. Much of this disappointment reflects who was chosen for surgery rather than any technical fault in the operation: patients whose symptoms are not actually caused by acid reflux predictably gain little benefit from a well-constructed wrap.

Individual factors measured before surgery, such as the amount of acid in the esophagus, the link between symptoms and reflux episodes, the type of symptoms, and how well the patient responded to acid-suppressing tablets, have each been linked to the outcome. However, most of that evidence comes from retrospective studies that used different definitions of success, so it is still unclear which factors matter independently once they are considered together.

Read more

This study will follow adults with objectively confirmed GERD who are scheduled for elective laparoscopic fundoplication at Minia University Hospitals. Before surgery, every participant undergoes the same standardized assessment: upper endoscopy, 24-hour pH-impedance monitoring off acid-suppressing medication, high-resolution manometry, measurement of height and weight, and questionnaires covering reflux symptoms, anxiety, depression and physical symptom burden. Participants then complete validated symptom questionnaires again at 1, 3, 6 and 12 months after the operation.

The main measure of success is "responder status" at 12 months, meaning at least a 50% improvement in the total GERD-HRQL symptom score compared with before surgery, supported by the patient's own rating of satisfaction. The investigators will analyze ten factors recorded before surgery to determine which of them independently predict this outcome, and will use the results to build and test a prediction tool that surgeons can apply during preoperative counseling.

The study does not assign any treatment. The type of wrap performed, either a complete (Nissen) or a partial posterior (Toupet) fundoplication, is chosen by the treating surgeon according to a prespecified rule based on esophageal motility, exactly as in routine practice. Taking part involves completing questionnaires and attending the usual follow-up appointments, and adds no additional procedural risk.

Read the detailed description

BACKGROUND AND RATIONALE Gastroesophageal reflux disease affects an estimated 10-20% of adults in Western populations, with a rising prevalence elsewhere. Most patients are controlled with lifestyle measures and proton-pump inhibitor (PPI) therapy, but a substantial subgroup has medically refractory disease, troublesome regurgitation, PPI dependence with concerns about long-term use, or a large hiatal hernia. For these patients, laparoscopic fundoplication remains the most durable and widely performed antireflux operation, and it normalizes esophageal acid exposure in the majority of appropriately selected patients.

Published series nonetheless report that a meaningful minority, commonly 10-30%, experience persistent or recurrent symptoms, troublesome side effects such as dysphagia or gas-bloat, or dissatisfaction with the outcome. Suboptimal results are frequently attributable not to technical failure but to patient selection. Operating on patients whose symptoms are not driven by acid reflux, for example those with functional heartburn or esophageal hypersensitivity, predictably yields poor symptomatic benefit despite a technically sound wrap.

Several preoperative factors have been individually associated with symptomatic outcome. Objective pathological acid exposure, a positive symptom-reflux association, predominance of typical symptoms, and a good preoperative response to acid-suppressive therapy have each been linked to favorable results. Atypical or extra-esophageal symptom predominance, normal acid exposure, high psychological burden, obesity, and certain motility abnormalities have been associated with less benefit. Much of this evidence derives from heterogeneous retrospective series with differing outcome definitions, and the independent contribution of each factor, when modeled together and adjusted for confounding within a contemporary diagnostic framework (Lyon Consensus; Chicago Classification version 4.0), remains incompletely defined.

OBJECTIVES Primary objective: to identify the independent preoperative predictors of clinically significant symptom improvement 12 months after laparoscopic fundoplication.

Secondary objectives: to estimate the proportion of patients achieving clinically significant symptom improvement at 12 months; to identify preoperative predictors of secondary outcomes including discontinuation of antisecretory therapy, resolution of regurgitation, and postoperative dysphagia and gas-bloat symptoms; to develop and internally validate a multivariable prediction model and an optional simplified risk score; and to examine the concordance between subjective symptom improvement and objective reflux control in the subgroup undergoing postoperative physiological retesting.

Primary hypothesis: pathological esophageal acid exposure, a positive symptom-reflux association, predominance of typical symptoms, and a good preoperative PPI response are each independently associated with higher odds of symptom improvement. Secondary hypothesis: high baseline psychological burden, atypical or extra-esophageal symptom predominance, normal acid exposure, and obesity are independently associated with lower odds of improvement.

DESIGN AND SETTING Prospective observational cohort study conducted in accordance with the STROBE statement and, for the prediction-model component, the TRIPOD reporting guideline. Consecutive patients meeting the eligibility criteria are enrolled at preoperative assessment and followed for 12 months after surgery. There is no randomization and no experimental allocation; the type of fundoplication is determined by a prespecified motility-based algorithm reflecting routine clinical practice. The study is conducted at the Department of Surgery, Minia University Hospitals, Faculty of Medicine, Minia University, a tertiary referral center for foregut surgery, with the option of additional collaborating centers applying the same protocol.

CANDIDATE PREOPERATIVE PREDICTORS Ten prespecified preoperative variables are recorded for every participant, with age and sex forced into the multivariable model as covariates: (1) pathological acid exposure, defined as acid exposure time greater than 6% on off-PPI 24-hour pH-impedance monitoring and/or a DeMeester score greater than 14.7, categorized as pathological versus borderline or normal; (2) symptom-reflux association, defined as symptom association probability at least 95% and/or symptom index at least 50% for the index symptom, categorized as positive versus negative; (3) symptom phenotype, categorized as predominantly typical (heartburn or regurgitation) versus atypical or extra-esophageal (cough, throat symptoms, non-cardiac chest pain); (4) PPI response, defined as at least 50% relief of the dominant symptom on standard- or double-dose PPI for at least 8 weeks, categorized as good versus poor; (5) esophageal body motility on high-resolution manometry using the Chicago Classification version 4.0, categorized as normal versus ineffective esophageal motility; (6) hiatal hernia size measured as axial hernia length on endoscopy, manometry or imaging, categorized as at least 3 cm versus less than 3 cm; (7) erosive esophagitis by Los Angeles grade at endoscopy, categorized as erosive (grades A to D) versus non-erosive; (8) body mass index from measured weight and height at baseline, categorized as at least 30 versus less than 30 kg/m2; (9) psychological burden, defined as a Hospital Anxiety and Depression Scale anxiety or depression subscale score of at least 8 and/or elevated somatization on the PHQ-15, categorized as high versus low; and (10) symptom duration, categorized as at least 5 years versus less than 5 years.

SURGICAL TECHNIQUE All operations are performed or directly supervised by experienced foregut surgeons using a standardized laparoscopic technique: complete hiatal dissection with preservation of the vagi, circumferential mobilization of the distal esophagus to achieve at least 2.5 cm of tension-free intra-abdominal length, posterior crural approximation, and division of short gastric vessels as required to construct a tension-free wrap. A complete (Nissen, 360-degree) fundoplication, fashioned as a short floppy 1.5-2 cm wrap calibrated over a 56-60 Fr bougie, is performed in patients with normal esophageal body motility. A posterior partial (Toupet, 270-degree) fundoplication is performed in patients with ineffective esophageal motility. Wrap type is recorded and included as a covariate and subgroup variable. Standardized antibiotic and venous thromboembolism prophylaxis, analgesia, and a stepwise postoperative diet are applied.

SCHEDULE OF ASSESSMENTS Assessments are performed at screening and baseline, at operation, and at 1, 3, 6 and 12 months postoperatively. Baseline assessment comprises informed consent and eligibility, demographics and history, upper gastrointestinal endoscopy, off-PPI 24-hour pH-impedance monitoring, high-resolution manometry, GERD-HRQL, GerdQ, HADS and PHQ-15, anthropometry, and antisecretory medication use. GERD-HRQL, GerdQ and medication use are repeated at 1, 3, 6 and 12 months; HADS and PHQ-15 and patient satisfaction at 6 and 12 months; anthropometry at 12 months. Adverse events are recorded at every postoperative contact. Postoperative endoscopy and pH-impedance are performed selectively, for persistent symptoms or as part of the objective-control substudy.

SAMPLE SIZE The primary analysis is a multivariable logistic regression predicting responder status. The number of candidate predictors in the final model is constrained by the number of events in the less frequent outcome category, applying a minimum of ten events per variable. Assuming a conservative non-responder proportion of 20% and a final model containing up to eight predictors, at least 80 non-responder events are required, corresponding to 400 patients with complete 12-month follow-up. Allowing for approximately 15% attrition, the target enrollment is 470 patients. With 400 evaluable patients, a predictor present in roughly 30% of the cohort is detectable with about 80% power at a two-sided alpha of 0.05 for an adjusted odds ratio of approximately 2.0, and the target satisfies published criteria for the minimum sample size required to develop a multivariable prediction model with acceptable shrinkage and precision.

STATISTICAL ANALYSIS Continuous variables are summarized as mean with standard deviation or median with interquartile range according to distribution, and categorical variables as counts and percentages. Responders and non-responders are compared using the t-test or Mann-Whitney U test and the chi-squared or Fisher exact test as appropriate. A multivariable binary logistic regression model is fitted with responder status as the dependent variable; candidate predictors are specified a priori, variables with a univariable association at p less than 0.10 and those of established clinical importance are entered up to the limit of eight predictors, and age and sex are forced into the model. Results are reported as adjusted odds ratios with 95% confidence intervals and two-sided p-values at an alpha of 0.05. Linearity of continuous predictors is assessed using restricted cubic splines where appropriate, and multicollinearity is checked using variance inflation factors. Discrimination is quantified by the C-statistic, calibration is assessed using a calibration plot and the Hosmer-Lemeshow test, and overall fit is summarized by the Nagelkerke R-squared. Internal validation uses bootstrap resampling with 1,000 replications to estimate optimism, derive a uniform shrinkage factor, and report an optimism-corrected C-statistic. A simplified integer risk score may be derived from the shrunken regression coefficients. If missingness exceeds 5% and is plausibly at random, multiple imputation by chained equations is used with results pooled by Rubin's rules, and a complete-case analysis is reported as a sensitivity analysis. Prespecified subgroup analyses include complete versus partial wrap and typical versus atypical symptom phenotype. Secondary binary outcomes are analyzed with logistic regression, and time to symptomatic recurrence is explored using Kaplan-Meier methods and Cox regression. No interim analysis is planned. Analyses will be performed in R version 4.3 or later and/or IBM SPSS Statistics.

BIAS MINIMIZATION Selection bias is reduced by enrolling consecutive eligible patients and reporting participant flow per STROBE. Outcome ascertainment uses validated self-administered instruments with prespecified definitions, and outcome assessors are, where feasible, independent of the operating team. Assessors are trained on the operational definitions, and source-data verification is performed on a random sample of records. All predictors and the analysis plan are specified before data lock to avoid data-driven model selection.

ETHICS The study is conducted in accordance with the Declaration of Helsinki and applicable local regulations. Ethical approval was granted by the Medical Research Ethics Committee (Institutional Review Board) of the Faculty of Medicine, Minia University (approval number 2132:9/26, dated 02 September 2026). Written informed consent is obtained from every participant. Because the study is observational and surgery is performed on routine clinical indications, it carries no incremental procedural risk beyond standard care; the principal burden is completion of questionnaires.

Being tested
Laparoscopic Nissen fundoplication, Laparoscopic Toupet fundoplication
Keywords
Fundoplication, Nissen fundoplication, Toupet fundoplication, Antireflux surgery, GERD-HRQL, Esophageal pH monitoring, High-resolution manometry
Medical subject headings
Gastroesophageal Reflux, Hernia, Hiatal, Esophagitis, Peptic, Barrett Esophagus

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Laparoscopic Nissen fundoplicationProcedure or surgery

    Also called Nissen fundoplication; complete 360-degree wrap

    Standardized laparoscopic complete 360-degree fundoplication with complete hiatal dissection, preservation of the vagi, circumferential mobilization of the distal esophagus to at least 2.5 cm of tension-free intra-abdominal length, posterior crural approximation, and division of short gastric vessels as required. Performed as part of routine clinical care and observed by the study.

  • Laparoscopic Toupet fundoplicationProcedure or surgery

    Also called Toupet fundoplication; posterior partial 270-degree wrap

    Standardized laparoscopic posterior partial 270-degree fundoplication using the same hiatal dissection and esophageal mobilization as for the complete wrap. Performed as part of routine clinical care and observed by the study.

Study groups in NCT07809620
Study groupRoleWhat they receive
Complete (Nissen) fundoplicationParticipants with normal esophageal body motility on high-resolution manometry (Chicago Classification version 4.0) who undergo laparoscopic complete 360-degree fundoplication, fashioned as a short floppy 1.5-2 cm wrap calibrated over a 56-60 Fr bougie. Allocation is by the treating team according to the prespecified motility-based algorithm reflecting routine care, not by the study.
Receives: Procedure: Laparoscopic Nissen fundoplication
Partial posterior (Toupet) fundoplicationParticipants with ineffective esophageal motility on high-resolution manometry (Chicago Classification version 4.0) who undergo laparoscopic posterior partial 270-degree fundoplication. Allocation is by the treating team according to the prespecified motility-based algorithm reflecting routine care, not by the study.
Receives: Procedure: Laparoscopic Toupet fundoplication

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Responder status: proportion of participants achieving clinically significant symptom improvement

    Proportion of participants classified as responders. A responder is a participant with a reduction of at least 50% in the total Gastroesophageal Reflux Disease Health-Related Quality of Life (GERD-HRQL) score relative to baseline, corroborated by the patient's global satisfaction rating. The GERD-HRQL comprises 10 symptom items each scored from 0 (no symptoms) to 5 (symptoms incapacitating), giving a total score from 0 to 50, with higher scores indicating worse reflux-related quality of life, together with a separate global item on satisfaction with present condition. The outcome is analyzed as a binary variable, responder versus non-responder, and modeled against ten prespecified preoperative predictors by multivariable logistic regression with age and sex forced as covariates.

    Measured: 12 months after surgery

Secondary outcomes (9)
  1. Change from baseline in total GERD-HRQL score

    Mean change from baseline in the total GERD-HRQL score. Range 0 to 50; higher scores indicate worse reflux-related quality of life, so a negative change indicates improvement.

    Measured: Baseline and 1, 3, 6 and 12 months after surgery

  2. Change from baseline in GerdQ score

    Mean change from baseline in the total Gastroesophageal Reflux Disease Questionnaire (GerdQ) score. The GerdQ has 6 items giving a total score from 0 to 18; higher scores indicate a greater burden and likelihood of GERD, so a negative change indicates improvement.

    Measured: Baseline and 1, 3, 6 and 12 months after surgery

  3. Discontinuation of antisecretory therapy

    Proportion of participants no longer taking any proton-pump inhibitor or histamine-2 receptor antagonist, ascertained by structured medication review.

    Measured: 12 months after surgery

  4. Resolution of regurgitation

    Proportion of participants reporting no troublesome regurgitation, ascertained from the regurgitation items of the GERD-HRQL.

    Measured: 2 months after surgery

  5. New or persistent dysphagia

    Proportion of participants reporting new or persistent dysphagia on a validated dysphagia score, and the proportion requiring endoscopic dilatation.

    Measured: 12 months after surgery

  6. Gas-bloat symptoms

    Proportion of participants reporting troublesome gas-bloat symptoms, including inability to belch and increased flatulence.

    Measured: 12 months after surgery

  7. Patient satisfaction

    Proportion of participants who report that they would undergo the operation again given the same circumstances.

    Measured: 6 and 12 months after surgery

  8. Postoperative morbidity graded by the Clavien-Dindo classification

    Proportion of participants experiencing any postoperative complication, graded by the Clavien-Dindo classification from grade I (any deviation from the normal postoperative course not requiring pharmacological, surgical, endoscopic or radiological intervention) to grade V (death). Higher grades indicate more severe complications.

    Measured: 30 days after surgery

  9. Reoperation and symptomatic recurrence

    Proportion of participants undergoing reoperation for a failed or complicated wrap, and proportion with symptomatic recurrence defined as return of troublesome reflux symptoms after an initial response.

    Measured: 12 months after surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Sep 2026
  2. Study start20 Sep 2026
  3. Primary completion20 Sep 2028 (estimated)
  4. Study completion20 Dec 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
470 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07809620
Sponsor's protocol ID
2132:9/26
Status last verified
Sep 2026
First submitted
3 Sep 2026
Last updated
22 Sep 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Gastroesophageal Reflux Disease and Hiatal Hernia, run by Minia University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 22 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Saleh K Saleh, MD (01201765401 ext. +2, salehkhairy@mu.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Responder status: proportion of participants achieving clinically significant symptom improvement (time frame: 12 months after surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Sep 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in